Prolactin receptor signal transduction in cells of the immune system

C V Clevenger, D O Freier and J B Kline

Department of Pathology and Laboratory Medicine, University of Pennsylvania Medical Center, Philadelphia, Pennsylvania 19104, USA

Introduction

Prolactin (PRL) was originally identified as a neuroendocrine hormone of pituitary origin (Riddle & Braucher 1931, Riddle et al. 1933). While the primary function of this hormone was initially thought to lie solely within the breast, the functional pleiotropism of this peptide with regards to reproduction, osmoregulation, and behavior was subsequently recognized (Nicoll 1974). Several lines of evidence have now also demonstrated an immunoregulatory role for this peptide. Structural analysis of PRL has revealed it to be related to members of the cytokine/hematopoietin family such as growth hormone (GH), erythropoietin, granulocyte–macrophage colony stimulating factor (GM-CSF) and the interleukins (IL) IL-2 to IL-7 (Bazan 1990). Synthesis of PRL is not limited to the hypophysis, as numerous extra-pituitary sites of PRL expression including the decidua, breast, and T lymphocytes have been detected (DiMattia et al. 1986, Montogomery et al. 1987, Clevenger et al. 1990, Gellersen et al. 1994, Ginsburg & Vonderhaar 1995, Mershon & Moore 1986, Clevenger & Plank 1997). The receptor for PRL (PRLr) is present on T and B lymphocytes and macrophages (Pellegrini et al. 1992, Dardenne et al. 1994). Acting through its receptor, PRL modulates immune system function by stimulating both cell proliferation and survival. Taken together, these data indicate that PRL acts at the endocrine, paracrine, and autocrine levels in regulating immune function (Gala 1991, Prystowsky & Clevenger 1994, Kooijman et al. 1996, Yu-Lee 1997). This review initially focuses on the immunoregulatory functions of PRL in the immune system, and then focuses on the structure/function relationships within the PRLr as they pertain to immunologically relevant signal transduction pathways.

Function of PRL as a cytokine within the immune system

Role as a mitogen


Manipulation of PRL levels in rodent models, followed by immunologic challenge (i.e. antigen or infection) has provided an additional in vivo confirmation of the immunostimulatory role for PRL. Reconstitution of an appropriate immune response following challenge with either sheep red blood cells or Escherichia coli lipopolysaccharide was achieved in hypophysectomized, immuno-compromised rats following administration of 40 µg PRL/rat per day (Berczi et al. 1981). Use of other pituitary hormones, or combinations thereof including GH, failed to restore the immunologic response of these animals. Mice treated with 2 mg PRL/kg per 12 h and subsequently exposed to Salmonella typhimurium demonstrated a 66% reduction in mortality (Di Carlo et al. 1993). The infusion of PRL also mediated a dramatic improvement in the survival of bromocriptine-treated mice after intraperitoneal injection of Listeria monocytogenes (Bernton et al. 1988). This effect was possibly due to a concomitant regulation by PRL of γ-interferon production by T lymphocytes. Finally, the conjoint treatment of intact mice with PRL and γ-interferon resulted in a 75% survival rate following a lethal dose of Toxoplasma gondii (Benedetto et al. 1995). In humans, decreases in PRL levels mediated by the administration of dopamine induced a transient, but significant, reduction in the overall responsiveness of isolated peripheral blood lymphocytes to mitogens (Devins et al. 1992, Bailey & Burchett 1997).
Figure 1 Immunologic homeostasis is a balance between the counteracting effects of PRL and glucocorticoids of lymphocyte progenitors. While glucocorticoids inhibit lymphocyte proliferation and trigger apoptosis, PRL stimulates proliferation and enhances cell survival. Concomitant addition of these hormones to lymphocytes in vitro induces a stasis with regards to viable cell numbers.

Role as a survival factor
During periods of stress, increased levels of PRL are released from the pituitary, approximately paralleling the secretion of corticotropin releasing factor (Kant et al. 1992). While necessary for the maintenance of overall metabolism and survival during periods of stress, one potentially undesirable effect of glucocorticoids is their inhibition of immune responses. While this inhibition occurs by many mechanisms, one of the principal causes of glucocorticoid-induced immunosuppression is its induction of apoptosis in T cell progenitor populations (Wyllie 1980, Evans-Storms & Cidlowski 1995). As described above, acute decreases in PRL levels in both rodent models and humans result in decreased immunoeffectiveness. A physiologic linkage between the immunosuppression induced by glucocorticoid excess or PRL deficiency has been recently obtained. While examining the effects of glucocorticoids on the PRL-dependent T-cell line Nb2, Witorsch and colleagues found that either pretreatment or concomitant treatment of Nb2 cells with PRL significantly inhibited glucocorticoid-induced apoptosis (Fletcher-Chiappini et al. 1993, Witorsch et al. 1993). While treatment with glucocorticoid led to a 10-fold reduction in viable cell number, concomitant treatment of Nb2 cultures with both PRL and glucocorticoid induced a relative stasis in the total number of viable cells. These studies also demonstrated that PRL in defined culture could inhibit the dexamethasone (Dex)-induced apoptosis of normal murine thymocytes. Thus, at the neuro–immune level, PRL and glucocorticoids appear to antagonize their respective actions, resulting in the appropriate titration of immune response (see Fig. 1).

Expression of PRL within the immune system
The observation of a PRL-like immunoreactivity in the medium of cultured lymphoblastoid cell lines initially triggered the speculation that lymphocytes could express PRL (DiMattia et al. 1986, Montogomery et al. 1987, Kenner et al. 1991). The function of this autocrine/paracrine PRL was subsequently demonstrated by the growth inhibitory effects of anti-PRL antiserum on mitogen-stimulated lymphocytes (Bernton et al. 1988, Hartmann et al. 1989, Clevenger et al. 1990). At the level of RNA, PRL expression is found only in T lymphocytes (Pellegrini et al. 1992). Molecular analysis of the promoter regions utilized in the synthesis of PRL has revealed that both the proximal and distal promoters of this gene locus are utilized in T cells (Gellersen et al. 1994). In the absence of expression of the transcription factor Pit-1, however, function of only the distal promoter was observed. Analysis of this distal PRL promoter region has revealed a lymphoid-specific enhancer element between −212 and −375 bp upstream from the transcription start site which demonstrated two protected regions when analyzed by footprint analysis using Jurkat T-cell lysates (Berwaer et al. 1994). Further study of the distal PRL promoter has indicated a role for cAMP, acting through protein kinase A and cAMP response element, and other as yet unidentified factors in the control of this transcriptional regulatory unit (Gellersen et al. 1995, Telgmann et al. 1997).

In vivo analysis of PRL function through targeted genetic disruption
An additional tool in the in vivo analysis of PRL function has been recently gained by the development of mice with targeted gene disruptions (‘knock-outs’) of both the PRL (Horsemann et al. 1997) and PRLr (Ormandy et al. 1997) loci. While examination of both knock-out progeny has revealed deficits in terminal mammary differentiation and fertility, no obvious defect in hematopoiesis or lymphopoiesis was observed. Flow cytometric analysis of the peripheral blood, spleen, thymus, and lymph nodes revealed normal numbers of both T and B cells in the PRL knock-out mouse. These data clearly indicate that PRL alone is not required for the development of normal numbers of immune system cells. Presumably other compensatory mechanisms, specifically the actions of other members of the cytokine family, enable normal lymphopoiesis. Significantly, the normal and stressed functions of the immune systems of either knock-out mouse have not been reported at the time of this review. Such studies may provide both confirmatory and novel insights into the role of PRL during an immune response.

Mediation of PRL function by PRLr structure
The expression of the PRLr on macrophages, and T and B cells has been confirmed at the protein and RNA levels (Clevenger et al. 1990, Pellegrini et al. 1992). Increases in the levels of PRLr expression can be effected by either
mitogen or cytokine stimulation (Clevenger et al. 1990, Dardenne et al. 1994). Confirmation that the PRLr mediates the effects of PRL has been demonstrated by the mitogenic properties of a cross-linking anti-PRLr antibody on the Nb2 T-cell line (Elberg et al. 1990). Three isoforms of PRLr have been cloned in the rat (see Fig. 2): the ‘short’ (PRLr-S, approximately 291 amino acids, approximately 45 kDa), ‘long’ (PRLr-L, approximately 592–598 amino acids, 80–85 kDa), and intermediate (PRLr-I, a deletion mutant missing amino acids 323–520 of the PRLr-L isoform, found in the PRL-dependent rat T-cell lymphoma line Nb2; 393 amino acids, approximately 65 kDa) (Boutin et al. 1988, 1989, Ali et al. 1991). In humans, two PRLr isoforms have been identified: the long (Boutin et al. 1989) and a novel intermediate isoform, recently identified in our laboratory (Clevenger et al. 1995a). All PRLr isoforms are homologous in their extracellular and transmembrane domain; alternative mRNA splicing accounts for the differing sizes of the cytoplasmic domain, with the exception of the Nb2 mutant form, which is believed to result from a mutation in the exon encoding for rat PRLr intracellular domain (Ali et al. 1991). The extracellular domain of the PRLr demonstrates homology via a tryptophan-serine box motif with the gene superfamily of cytokine receptors that includes the receptors for IL-2 to IL-7, GM-CSF, GH, and erythropoietin (Bazan 1989).

Structure/function analysis of the intracellular/signaling domain of the PRLr has indicated that four conserved structural motifs, present in the superfamily of cytokine receptors, namely the box 1, variable box (‘V box’), box 2 and extended box 2 (‘X box’) are present in this receptor (Ihle & Kerr 1995). The box 1 motif consists of a hydrophobic proline-rich region and presents some similarity with the Src homology 3 (SH3) binding sites. The box 2 motif, present in PRLr-I and PRLr-L but absent in PRLr-S, is rich in hydrophobic and acidic amino acid residues. The intervening region between box 1 and box 2 is the V box; only a partial sequence of this motif is found within the PRLr-S. On the carboxy side of the box...
2 motif resides the X box, a region poorly conserved between the cytokine receptors, required for the function of some members of the cytokine receptor family (Miura et al. 1993). Functional analysis of the different PRLr isoforms in a transient promoter/reporter assay system has found that both the PRLr-L and the PRLr-I, but not the PRLr-S, can initiate transcription from a PRL-responsive promoter in each chain (‘in trans’) reduced PRLr function by 90%. In contrast, replacement of two tyrosine residues on one intracellular chain (‘in cis’) led to a complete ablation of signaling and proliferation. These data support the hypothesis that PRLr tyrosine transphosphorylation serves as an important proximal signaling mechanism for this receptor complex.

As no PRL-responsive tissue has been shown to express only a single PRLr isoform (Nagano & Kelly 1994), the formation of heterodimeric complexes within cells of the immune system may be more of a rule than an exception. To test the functional significance of PRLr isoform heterodimerization, chimeric receptor constructs were recently utilized by our laboratory (Chang & Clevenger 1996). These chimeric receptors contained the extracellular domains of the human GM-CSFRα or β subunit, termed α or β respectively, and the transmembrane and intracellular domains of the rat PRLr-I and PRLr-S isoforms. When these chimeras (termed αS, αI, βS, or βI) were co-expressed in the IL-3-dependent B lymphocyte Ba/F3 line, ligand-induced dimerization of the extracellular domains induced a specific one-to-one pairing of the PRLr intracellular domains. While transfectants expressing the αI/βI homodimer demonstrated ligand-induced function equivalent to the wild-type PRLr, expression of either homo- or heterodimers of the PRLr-S isoform (αS/βS, αS/βI, or αI/βS) acted in a dominant negative manner inhibiting both ligand-driven proliferation and receptor-associated signaling. These data support the hypothesis that PRLr tyrosine transphosphorylation serves as an important proximal signaling mechanism for this receptor complex.

As no PRL-responsive tissue has been shown to express only a single PRLr isoform (Nagano & Kelly 1994), the formation of heterodimeric complexes within cells of the immune system may be more of a rule than an exception. To test the functional significance of PRLr isoform heterodimerization, chimeric receptor constructs were recently utilized by our laboratory (Chang & Clevenger 1996). These chimeric receptors contained the extracellular domains of the human GM-CSFRα or β subunit, termed α or β respectively, and the transmembrane and intracellular domains of the rat PRLr-I and PRLr-S isoforms. When these chimeras (termed αS, αI, βS, or βI) were co-expressed in the IL-3-dependent B lymphocyte Ba/F3 line, ligand-induced dimerization of the extracellular domains induced a specific one-to-one pairing of the PRLr intracellular domains. While transfectants expressing the αI/βI homodimer demonstrated ligand-induced function equivalent to the wild-type PRLr, expression of either homo- or heterodimers of the PRLr-S isoform (αS/βS, αS/βI, or αI/βS) acted in a dominant negative manner inhibiting both ligand-driven proliferation and receptor-associated signaling. Thus, these results demonstrated that functional pairing of structures other than the box 1 motif, such as the V box, box 2, X box, and the carboxy tail of the PRLr, are required for mitogenesis and activation of Jak2 and Fyn. We have extended these studies to examine the structural stoichiometry of the PRLr complex (Chang et al. 1998). Specifically, the numerical contributions of the membrane-proximal region of the intracellular domain (i.e. box 1/V box/box 2/X box motifs) and the carboxy-terminal tyrosines to PRLr function were tested. Regardless of the number of V box or box 2 motifs present in the ligand-induced
chimeric receptor complexes, the absence of one of the PRLr carboxy-terminal tails precluded proliferation. In response to ligand, such complexes were incapable of activating-associated signaling pathways, as evidenced by a lack of Jak2 and Fyn activation and an absence of Sos phosphorylation. In comparison, replacement of any one of the carboxy-terminal tyrosines within the dimerized PRLr complex resulted in intermediate levels of ligand-induced signaling and proliferation. As seen in Fig. 3, however, replacement of these tyrosine residues either in trans or in cis resulted in either significantly diminished or absent PRLr function. These data demonstrate that the tyrosine residues at 309 and 382, as well as additional residues within the carboxy terminus of the dimerized PRLr complex, contribute to PRL-driven signaling and proliferation. Furthermore, these findings would indicate that the PRLr, like the receptor tyrosine kinases, may utilize a transphosphorylation mechanism in the initial activation of signaling from the dimerized receptor complex.

PRLr signaling in the immune system

**Proximal signaling-protein tyrosine kinases**

As schematized in Fig. 4, the functions of the PRL/PRLr complex in the immune system are mediated by receptor-associated signaling proteins. Lacking intrinsic enzymatic activity, ligand-induced dimerization of the PRLr complex serves to activate these associated signaling cascades. Some of the most proximal kinases activated during PRLr signaling are members of the JAK and Src families of protein tyrosine kinases (PTK). The Jak family of PTKs include JAKs 1–3 and Tyk2 (Silvennoinen et al. 1993, Ihle & Kerr 1995) and are associated with early transduction events in all members of the cytokine receptor superfamily. Receptor-associated JAK2 is activated rapidly (within 5 min) after engagement of PRL by its receptor (DaSilva et al. 1994, Lebrun et al. 1994, Rui et al. 1994a,b). Use of somatic cell genetics has determined that one substrate for the activity of JAK family members is the Stat
family of signal transduction factors (Darnell et al. 1994). PRL-induced tyrosine phosphorylation of Stat 5, resulting in Stat dimerization and nuclear translocation, has been demonstrated in lymphocytes (Gilmour & Reich 1994). Stat 5 transactivation is required for transcription initiation for several cytokine/PRL-regulated gene products including interferon regulatory factor 1, cyclin B and histone H3 (Yu-Lee 1990, Clevenger et al. 1992). While the JAK–Stat pathway provides a necessary signal for programmed gene expression and cell differentiation in lymphoid tissues, recent data have indicated that this pathway is not necessary for cell proliferation or survival (Fujii et al. 1995, Quelle et al. 1996). Two other PRLr-associated pathways may provide additional signals for lymphocyte proliferation and survival. By phosphorylating the PRLr at carboxy-terminal tyrosines, Jak2 may enable the association of the signaling adaptor protein SHC with the PRLr, which in turn activates the Sos/Vav/Sos/Ras/Rac/Raf/MAPK signaling cascade (Erwin et al. 1995). A second pathway which may mediate a PRLr-specific proliferative signal is that associated with the Src-family member p62fyn. Fyn is also activated rapidly after ligand-induced PRLr dimerization. As shown by this laboratory and others (Clevenger & Medaglia 1994, Li et al. 1996), direct substrates for PRL-activated Fyn include the guanine-nucleotide exchange factors Sos and Vav, which serve to activate both Ras and Rac G-proteins. Acting as allosteric activators, both Ras and Rac serve to activate kinase cascades that ultimately activate the dual specificity kinase MAPK and S6 kinase that can directly phosphorylate and activate numerous transcription factors, such as Jun, Fos, p62, etc. While at face value the Jak/Stat and Shc/Grb2/Vav/Sos/Ras/Rac/Raf/MAPK path-ways may appear as linear cascades, multiple interactions between the signaling complexes associated with the PRLr may occur. Indeed, the documented interactions between Fyn–Vav, Jak–Fyn, Grb2–Vav, and Jak2–Raf indicate the generation of proximal receptor-based signals occurs as the result of associated multimeric transduction complexes (Xia et al. 1996, Wang et al. 1997).

Mediators of PRL-induced lymphocyte proliferation – Vav

The structure of Vav is complex, and has multiple domains of potential functional significance identified on the basis of structural homology (Katzav et al. 1989, 1991, Adams et al. 1992, Feig 1994). In its amino terminus, two domains with homology to a helix–loop–helix-like motif and a leucine zipper domain have been identified; these domains may serve to facilitate the interaction of Vav with other proteins and suppress an intrinsic transforming capability of this protein. Centrally located within Vav are two nuclear localization motifs, a cysteine-rich diacylglyceride (DAG) binding site, and a Dbl-GEF motif. The presence of a Dbl-GEF motif suggested that Vav may serve as a guanine nucleotide exchange factor (GEF) to the cytoskeleton-associated GTP binding protein Rho/Rac and contribute to cytoskeleton organization. Indeed recent data have shown Vav can function as a GEF for Rac-1 in vitro and in vivo, leading to activation of the JNK/Jun signal transduction pathway (Crespo et al. 1997). Some data, however, indicate that Vav may also associate and/or activate Ras GEFs during activation of the T-cell receptor and immunoglobulin (Gulbins et al. 1993, 1994c, Clevenger et al. 1995b). Finally, in the carboxy terminus of Vav reside two SH2 and one SH3 domains, with striking overall homology to the signal transduction adaptor protein Grb-2.

The presence of several structural domains within Vav would suggest that this molecule may participate in more than one signal transduction function. Vav is widely expressed in the mature lymphoid, myeloid, and erythroid lineages, and selectively in their differentiating precursors (Katzav et al. 1989, 1993, Coppola et al. 1991, Bustelo et al. 1992, 1993, Katzav 1993). Marked variations in the expression of Vav mRNA and protein were observed in developing thymic T-lymphocyte populations (Bustelo et al. 1993), suggesting that the regulation of this protein may be important during the development and expansion of T cells. The phosphorylation of Vav has been observed after stimulation of the T-cell receptor (Gulbins et al. 1993), membrane immunoglobulin (Gulbins et al. 1994c), Fc receptor (Margolis et al. 1992), interferon α receptor (Platanius & Sweet 1994), c-kit (Alai et al. 1992), PRLr (Clevenger et al. 1995b), and the receptors for IL-1 (Gulbins et al. 1994a) and -2 (Evans et al. 1993). Anti-sense experiments have revealed that the inhibition of Vav expression in embryonic stem cells prevents their in vitro differentiation into mature hematopoietic elements (Wulf et al. 1993). These findings, however, have been contradicted in a recent study using vav−/− mouse embryonic stem cells (Zhang et al. 1994), as normal hematopoietic differentiation was observed in this system in vitro. Study of this knock-out in vivo in chimeric mice, however, has revealed decreased numbers of circulating T and B cells and impaired receptor-mediated signal transduction (Zhang et al. 1995). Thus, although these data question the role of Vav during embryonic hematopoiesis, they support its role as an important signaling factor involved in the immune response. Stimulation of both the T-cell receptor and PRLr in T-cell lines and surface immunoglobulin in B cells stimulates Vav-associated GEF activity (Gulbins et al. 1993, Clevenger et al. 1995b). Taken together, these data indicate that Vav expression contributes to immune system function, mediating critical growth and differentiation signals from ligand-stimulated hematopoietic receptors.

A GEF activity associated with Vav has been demonstrated during stimulation of the T-cell receptor (Gulbins et al. 1993) and membrane immunoglobulin (Gulbins et al. 1994c). This activity appeared to be regulated by PTks (Gulbins et al. 1993), and by phorbol esters and DAG
(Gulbins et al. 1994a,b). Regulation of Vav function by DAG was not unanticipated, given the presence of a cysteine-rich DAG-binding domain that is necessary for the transforming potential of oncogenic Vav (Coppola et al. 1991). The SH2 domain in Vav appears necessary for its interaction with the signaling adaptor proteins GRB2 and Shc in the Jurkat cell line (Ramos-Morales et al. 1994). Indeed, screening of phosphopeptide libraries indicates a preferential interaction of Vav’s SH2 domain with the amino acid sequence phospho-Tyr-Met-Glu-Pro (Songyang et al. 1994). Mutations within this domain have been found to ablate oncogenic Vav’s transforming potential (Katzav 1993), suggesting that protein–protein interactions are necessary for this potential. Vav contains an intrinsic oncogenic potential; removal or mutation within its amino-terminal helix–loop–helix-like domain produces a protein with potent transforming capabilities (Katzav et al. 1989, 1991, Coppola et al. 1991). Indeed, the oncogenic form of Vav was discovered before its normal proto-oncogenic counterpart, through the screening of esophageal carcinoma genomic DNA for transforming potential (Katzav et al. 1989). These data again suggest that protein–protein interactions directed by the structural domains within Vav may critically regulate its signaling functions.

Indeed, this point is critical in understanding the role of Vav in PRLr signaling. While anti-sense ablation of Vav inhibits prolactin-induced proliferation in Nb2 cells (Clevenger et al. 1995b), other preliminary experiments in our laboratory have shown a direct interaction between the PRLr and Vav, as well as a possible downstream role for Vav in gene expression or regulation. To identify regions within the PRLr intracellular domain necessary for Vav interaction, human PRLr deletion mutants were expressed and purified as glutathione-S-transferase (GST) fusion proteins and analyzed for their capacity to bind Vav from Nb2 lysates as well as recombinant Vav. PRLr residues 323 to 527 were found necessary for in vitro association with both wild-type and recombinant forms of Vav. Interestingly, this region is deleted in the Nb2 form of the PRLr and suggests the PRL-induced proliferation of Nb2 cells may result from aberrant activation or altered ternary complex formation.

Following PRL stimulation of Nb2 cells, it was also found that Vav transiently translocates to the nucleus (Clevenger et al. 1995b). Within the nucleus, Vav could interact with several proteins via its leucine-rich, acidic-rich, SH2 and SH3 domains. It has been recently found that Vav can interact with heterogenous ribonucleoprotein K in vitro and in vivo (Hobert et al. 1994), and the putative transcriptional regulator ENX-1 (Hobert et al. 1996). Although the significance of these interactions is currently unknown, such a connection between these proteins may represent novel mechanisms regulating gene expression. Thus, through its interaction with both receptors and transcription factors, Vav may function both at the cell membrane and within the nucleus.

Mediators of PRL-induced lymphocyte survival – Bag-1

While signaling through the above cascades provides a molecular framework for the immunoproliferative effects of PRL, the biochemical basis for the anti-apoptotic effects of this hormone on lymphocyte progenitors has been largely uncharacterized. Recent studies have suggested that members of the Bcl-2 family, or associated proteins may regulate this phenomenon. In examining the PRL-dependent pro-T cell line Nb2, Buckley and his colleagues have demonstrated a significant modulation in the RNA levels of both Bcl-2 and Bax in response to PRL (Leff et al. 1996), while more modest changes were noted at the protein level. Given similar findings by our laboratory (Clevenger et al. 1997), we have recently focused our attention on the Bcl-2-associated protein Bag-1 (for Bcl-2-associated anti-death gene 1). Bag-1 encodes for a 219 amino acid protein, which migrates in SDS-PAGE at 29 kDa (Takayama et al. 1995). When co-expressed with Bcl-2 in Jurkat cells, a significant increase in resistance to cell death triggered by treatment with anti-Fas antibody or staurosporine was observed (Takayama et al. 1995). Our findings revealed that removal of ligand from the PRL-dependent rat T-cell line Nb2, or the IL-3-dependent murine pro-B cell line Ba/F3, induced significant decreases in the overall Bag-1 protein levels before the earliest detectable evidence for cellular apoptosis (Clevenger et al. 1997). Similarly, Dex treatment of the Nb2 line lead to dramatic decreases in overall Bag-1 levels, again before the onset of Dex-induced apoptosis. Exposure of Dex-treated Nb2 cells to PRL inhibited apoptosis (10–20% cell death in cells treated with PRL and Dex, vs >90% cell death in Dex-treated cells); examination of lysates from these cultures by anti-Bag-1 immunoblot analysis found intermediate levels of cellular Bag-1. Further corroboration of these findings was obtained by the study of SFJCD1 cells. SFJCD1 represents a spontaneous subline of Nb2 which is both PRL-independent and Dex-resistant, unlike the parental Nb2 cells. Examination of the SFJCD1 subline during Dex treatment or PRL withdrawal found constitutively high levels of Bag-1 in cells whose viability remained high, despite such treatments. To confirm that the regulation of Bag-1 levels directly contributed to cellular resistance to apoptosis, the IL-3-dependent Ba/F3 line was transfected with a Bag-1 expression construct. Overexpression of Bag-1 in Ba/F3 rendered the transfec
tants completely growth factor independent. The cellular survival of both IL-2-dependent cell lines and mitogen-stimulated normal peripheral blood lymphocytes also appears to be regulated by Bag-1 levels (Adachi et al. 1996). These findings collectively demonstrate that Bag-1 protein levels are intimately linked to the survival of cytokine-dependent lymphoid lines and normal lymphocytes, and that the enhanced expression of Bag-1 promotes lymphocyte survival.


Downloaded from Bioscientifica.com at 12/12/2018 07:37:49PM via free access
Initial in vitro studies indicated that Bag-1 could interact with Bcl-2, and could potentiate the effects of Bcl-2 in vivo (Takayama et al. 1995). Previous data had suggested that Bcl-2 could weakly interact with the p72–74 kDa serine/threonine kinase Raf-1. Although no evidence has been found for a direct phosphorylation of Bcl-2 by Raf-1, the synergy between these molecules in inhibiting apoptosis when co-transfected (Wang et al. 1994), suggested that other molecules could contribute to their interaction. Indeed, when tested by two separate laboratories, Bag-1 interacted both in vitro (i.e. recombiant–recombiant protein) and in vivo (i.e. by co-immunoprecipitation, and yeast two-hybrid screening) with both Raf-1 and Bcl-2 (Wang et al. 1996, Olivier et al. 1997). The Bag-1–Raf interaction may lead to a modest increase in the overall level of kinase activity of Raf-1, as found when both proteins are overexpressed in human 293 or insect SF9 cells (Wang et al. 1996). These studies have demonstrated that the Bag-1–Raf interaction is mediated by the carboxy termini of both molecules. Bag-1 also appears capable of forming complexes with heat shock proteins (Zeiner & Gehring 1995, S Takayama, S Krajewski, M Krajewski, S Kitada, JM Zapata, K Kochel, D Knee, GJ Miller, D Scudiero, G Tudor, EA Sausville & JC Reed, unpublished observations) in the presence of ATP. Thus, while the potential effector molecules for Bag-1 function have been identified, the precise mechanisms through which Bag-1 affects these functions remains a fertile area of future investigation.

Clinical applications and future directions

Several lines of evidence suggest that the manipulation of PRL levels may have significant clinical utility. The increases in PRL levels in patients undergoing cardiac allograft rejection (Carrier et al. 1987), modulation of graft survival (Comsa et al. 1975), the decrease in immuno-responsiveness of humans receiving dopamine in the intensive care setting (Devis et al. 1992, Martinelli et al. 1996, Zellweger et al. 1996, Bailey & Burchett 1997), and the association between increased PRL levels and severity of systemic lupus erythematous (SLE) (McMurray et al. 1992, 1993) support the potential utility of pharmacotherapy aimed at the PRL/PRLr complex. Indeed, the treatment of SLE patients with bromocriptine appears to have some efficacy in improving the course of disease (McMurray et al. 1995). While the data obtained from these endocrine-targeted therapies (i.e. bromocriptine) appear encouraging, the development of advanced pharmacologic agents capable of blocking PRL/PRLr expression and/or action at both the endocrine and autocrine/paracrine levels may hold even greater promise. While our knowledge of the relationship of PRL/PRLr to the immune system has advanced tremendously over the past 20 years, significant questions remain regarding both the physiologic and molecular mechanisms of action of this hormone complex. Specifically, little is known regarding the stimuli or the pathways that regulate the expression of both PRL and the PRLr in lymphocytes. The functional significance and the regulation of expression of the human PRLr isoforms has not been characterized. Finally, the effects of PRL on the expression and function of other cytokines and their receptors within the immune system remains to be determined. Further study of the mechanisms of the PRL/PRLr complex within the immune system may therefore provide crucial insights into the function and ultimate therapeutic potential of this receptor complex.

Acknowledgements

This work was funded in part by grants R29 AI33510, R01 DK50771 and R01 CA69294 from the National Institutes of Health to C V C. J B K is a recipient of National Research Service Award F32 DK09727 from the National Institutes of Health. C V C is also a recipient of a Junior Faculty Research Award JFRA-588 from the American Cancer Society.

References


Adams JM, Houston H, Allen J, Lint T & Harvey R 1992 The hematopoietically expressed vav proto-oncogene shares homology with the dbl GDP-GTP exchange factor, the bcr gene and a yeast gene (CDC24) involved in cytoskeletal organization. Oncogene 7 611–618.


Ali S, Pellegrini I & Kelly PA 1991 A prolactin-dependent immune cell line (Nb2) expresses a mutant form of prolactin receptor. Journal of Biological Chemistry 266 20110–20117.


Bazan JF 1989 A novel family of growth factor receptors: a common binding domain in the growth hormone, prolactin, erythropoietin and IL-6 receptors, and the p75 IL-2 receptor beta-chain. Biochemical and Biophysical Research Communications 164 788–795.


Cleverger CV & Medaglia MV 1994 The protein tyrosine kinase p59fyn is associated with prolactin receptor and is activated by prolactin stimulation of T-lymphocytes. \textit{Molecular Endocrinology} \textbf{8} 674–681.


Cleverger CV, Ngø W, Sokol DL, Lugm AM & Gewirtz AM 1995b Vav is necessary for prolactin-stimulated proliferation and is translocated into the nucleus of a T-cell line. \textit{Journal of Biological Chemistry} \textbf{270} 13246–13253.

Cleverger CV, Thickman K, Ngø W, Chang W-P, Takayama S & Reed JC 1997 Role of Bag-1 in the survival and proliferation of the cytokine-dependent lymphocyte lines, Ba/F3 and Nb2. \textit{Molecular Endocrinology} \textbf{11} 608–618.


Gilmore KC & Reich NC 1994 Receptor to nucleus signaling by prolactin and interleukin 2 via activation of latent DNA-binding factors. \textit{Proceedings of the National Academy of Sciences of the USA} \textbf{91} 6850–6854.


Downloaded from Bioscientifica.com at 12/12/2018 07:37:49PM via free access


Quelle FW, Wang D, Nosaka T, Thierfelder WE, Stravopodis D, Weinstein Y & Ihle JN 1996 Erythropoietin induces activation of...
Stat5 through association with specific tyrosines on the receptor that are not required for a mitogenic response. *Molecular and Cellular Biology* 16 1622–1631.


Riddle O & Braucher PF 1931 Studies on the physiology of reproduction in birds. XXX. Control of the special secretion of the crop-gland in pigeons by an anterior pituitary hormone. *American Journal of Physiology* 97 617–625.


Wulf GM, Adra CN & Lim B 1993 Inhibition of hematopoietic development from embryonic stem cells by antisense vav RNA. *EMBO Journal* 12 5065–5074.


Zeiner M & Gehring U 1995 A protein that interacts with members of the nuclear hormone receptor family: Identification and cDNA cloning. *Proceedings of the National Academy of Sciences of the USA* 92 11465–11469.


Received 23 October 1997
Accepted 11 December 1997